WCN24-2352 Improved Proteinuria Reduction with the use of Sparsentan and Targeted Release Budesonide in advanced IgAN

WCN24-2352 Improved Proteinuria Reduction with the use of Sparsentan and Targeted Release Budesonide in advanced IgAN

Saved in:

Bibliographic Details
Main Authors:	Neeharik Mareedu, Praveen Errabelli
Format:	Article
Language:	English
Published:	Elsevier 2024-04-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924004789
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

WCN24-2219 TRF-BUDESONIDE AND SPARSENTAN AS AN INITIAL THERAPY FOR PRIMARY IgA NEPHRITIS
by: Neeharik Mareedu, et al.
Published: (2024-04-01)

WCN25-716 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS IN IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE PHASE 3 APPLAUSE-IgAN STUDY
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

WCN25-1884 SPARSENTAN (SPAR) AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE SPARTAN TRIAL
by: Chee Kay Cheung, et al.
Published: (2025-02-01)

WCN24-847 SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL
by: Jonathan Barratt, et al.
Published: (2024-04-01)

WCN24-752 CONCOMITANT SPARSENTAN AND SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS (SGLT2is) IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN) IN THE PROTECT OPEN-LABEL EXTENSION (OLE)
by: Radko Komers, et al.
Published: (2024-04-01)

WCN25-932 STEROID (SYSTEMIC OR ENTERIC RELEASED BUDESONIDE) REFRACTORY NEPHROTIC RANGE PROTEINURIA IN IgA NEPHROPATHY; CAN TACROLIMUS BE AN ALTERNATIVE?- A CASE SERIES
by: RAJA SINGHAL, et al.
Published: (2025-02-01)

WCN25-52 EPIDEMIOLOGY OF IMMUNOGLOBULIN A NEPHROPATHY (IgAN) AND OCCURRENCE OF PROTEINURIA IN CHINA: EVIDENCE FROM SYSTEMATIC REVIEW AND META-ANALYSIS
by: Zhaoxin Chen, et al.
Published: (2025-02-01)

WCN25-1898 IMPLICATIONS OF PROTEINURIA REMISSION ON ESTIMATED GLOMERULAR FILTRATION RATE (eGFR) TRAJECTORY IN PATIENTS (Pts) WITH IgA NEPHROPATHY (IgAN) IN PROTECT
by: Bruce Hendry, et al.
Published: (2025-02-01)

WCN25-4378 OUTCOME OF USE OF ENTERIC RELEASED BUDESONIDE IN IgA NEPHROPATHY PATIENTS WITH NEPHROTIC AND SUBNEPHROTIC PROTEINURIA PRESENTATIONS: PROSPECTIVE COMPARATIVE STUDY IN TERTIARY CARE CENTRE
by: RAJA SINGHAL, et al.
Published: (2025-02-01)

Prognostic Value of Urinary Biomarkers in Proteinuria Progression in IgA Nephropathy Patients Treated with Budesonide
by: Christodoulos Keskinis, et al.
Published: (2025-04-01)

WCN25-799 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IgAN STUDY
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

WCN24-846 SPARSENTAN RECEPTOR OCCUPANCY MODELING, CLINICAL ACTIONS, AND SAFETY
by: Bruce Hendry, et al.
Published: (2024-04-01)

WCN24-773 SPARSENTAN AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY: PRELIMINARY FINDINGS FROM THE SPARTAN TRIAL
by: Chee Kay Cheung, et al.
Published: (2024-04-01)

WCN24-1506 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY
by: Vlado Perkovic, et al.
Published: (2024-04-01)

WCN25-1585 A Phase 1/2 Trial of Zigakibart in IgA Nephropathy (IgAN)
by: Jonathan Barratt, et al.
Published: (2025-02-01)

WCN25-778 AFFINITY study: 1-year results of atrasentan in IgA nephropathy (IgAN)
by: Jonathan Barratt, et al.
Published: (2025-02-01)

WCN25-1084 INTERNATIONAL RISK-PREDICTION TOOL IN IgAN AND THE PROGNOSTIC IMPLICATIONS OF CRESCENTS
by: Beatriz Mendes, et al.
Published: (2025-02-01)

WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

WCN24-1774 eGFR DECLINE IN PATIENTS WITH IgAN TREATED WITH NEFECON OR PLACEBO: RESULTS FROM THE 2-YEAR NefIgArd PHASE 3 TRIAL
by: Richard Lafayette, et al.
Published: (2024-04-01)

WCN25-4528 POST TRANSPLANT CRESCENTIC IgAN- FIRST CASE SERIES FROM INDIA
by: NITISH THAKUR, et al.
Published: (2025-02-01)

WCN25-2522 ORIGIN Extend: A Long-Term Extension Study of Atacicept in IgAN
by: Jonathan Barratt, et al.
Published: (2025-02-01)

WCN24-2269 MODERATE-SEVERE INTRARENAL ARTERIOSCLEROSIS AND CIRCULATING GDF-15 LEVELS MAY INFLUENCE THE CARDIAC-RENAL PROGNOSIS OF IgAN PATIENTS
by: Hong Cheng, et al.
Published: (2024-04-01)

WCN24-1776 NEFECON EFFECT ON QUALITY OF LIFE IN PATIENTS WITH IgAN: SF-36 RESULTS FROM THE PHASE 3 NeFIgArd TRIAL
by: Jonathan Barratt, et al.
Published: (2024-04-01)

Enteric-coated Mycophenolate Sodium plus hydroxychloroquine therApy versus hydroxychloroquine for the Remission of Proteinuria in IgA Nephropathy (EMSAR-IgAN trial): study protocol for a randomised trial
by: Lihua Wang, et al.
Published: (2025-04-01)

WCN24-577 STEROID CONTROVERSIES IN THE TREATMENT OF IGANEPHROPATHY: CLINICAL CASE OF RAPID PROGRESSIVE IGAN
by: Olga Chub
Published: (2024-04-01)

WCN24-1777 NEFECON TREATMENT PROVIDES KIDNEY BENEFITS FOR PATIENTS WITH IgAN THAT EXTEND TO THOSE WITH LOW LEVELS OF UPCR: A SUB-ANALYSIS OF THE PHASE III NefIgArd TRIAL
by: Jonathan Barratt, et al.
Published: (2024-04-01)

A Targeted-Release Formulation of Budesonide for the Treatment of IgA Nephropathy Patients With Severe Renal Impairment
by: Yan Ouyang, et al.
Published: (2025-03-01)

WCN24-774 PRELIMINARY FINDINGS FROM THE PHASE 2 EPPIK STUDY OF SPARSENTAN IN PEDIATRIC PATIENTS WITH SELECTED PROTEINURIC GLOMERULAR DISEASES
by: Radko Komers, et al.
Published: (2024-04-01)

WCN25-2470 Long-term Results from the ORIGIN Phase 2b Study of Atacicept for the Treatment of IgAN
by: Vivekanand Jha, et al.
Published: (2025-02-01)

WCN24-1268 End-Stage Kidney Disease (ESKD) and Chronic Kidney Disease (CKD) Progression among a Hispanic/Latino Population with Primary Immunoglobulin A Nephropathy (IgAN)
by: John Sim, et al.
Published: (2024-04-01)

WCN24-2673 COMPLEMENT LEVELS AND PROTEINURIA IN LUPUS NEPHRITIS CORRELATIONS AND TREATMENT RESPONSE
by: Maria Izabel de Holanda, et al.
Published: (2024-04-01)

WCN25-318 FELZARTAMAB DURABLY REDUCES DISEASE RELEVANT BIOMARKERS THROUGH TARGETING OF CD38+ PLASMA CELLS AND PLASMABLASTS, THE UPSTREAM DRIVERS OF IgA NEPHROPATHY (IgAN)
by: Lisa Kivman, et al.
Published: (2025-02-01)

Exploring the mechanism of proteinuria reduction by hydroxychloroquine in IgA nephropathy using network pharmacology and molecular mocking
by: Meiqi Lu, et al.
Published: (2025-07-01)

Real-world assessment of sparsentan’s drug safety framework
by: Wenjing Fu, et al.
Published: (2025-12-01)

WCN24-2599 EFFICACY AND SAFETY OF BUDESONIDE IN IGA NEPHROPATHY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
by: João Lucas de Magalhães Leal Moreira, et al.
Published: (2024-04-01)

Burden of corticosteroid therapy in patients with immunoglobulin A nephropathy (IgAN): a systematic literature review
by: Sarah N. Ali, et al.
Published: (2025-05-01)

WCN25-3679 Open label, single arm, multicenter, prospective study on oral enteric coated budesonide therapy for primary IgA nephropathy
by: SANSHRITI CHAUHAN, et al.
Published: (2025-02-01)

WCN24-1365 KIDNEY ELASTOMETRY AND X-FLOW ALGORITHMS:NEW METHODS TO INTERROGATE THE PROTEINURIA AND EFFECTS OF EMPAGLIFLOZIN
by: P.I.E.T.R.O. IULIANIELLO, et al.
Published: (2024-04-01)

Exploring the molecular mechanism of budesonide enteric capsules in the treatment of IgA nephropathy based on bioinformatics
by: Mengshu Lin, et al.
Published: (2025-08-01)

WCN24-1863 Towards an IgA Nephropathy Atlas
by: Julio Saez-Rodriguez, et al.
Published: (2024-04-01)